The FDA is expected to make decisions about therapies for small-cell lung cancer and myelodysplastic syndrome next month. The US Food and Drug Administration (FDA) is expected to decide in June ...

A new study suggests that starting a patient on preferred targeted therapy within 1 year of metastatic non-small cell lung cancer diagnosis can still improve overall survival, when compared to other ...

This story was originally published by ProPublica. In late 2020, Dr Debby Day said her bosses at Cigna gave her a stark warning. Work faster, or the company might fire her.

For years, the Department of Veterans Affairs has provided disability compensation for cancers and other diseases connected to Agent Orange exposure, but vets who were exposed to the herbicide on a US ...

Cigna tracks every minute that its staff doctors spend deciding whether to pay for health care.

Experts have released recommendations for managing pregnant patients who have NIPT results suggesting they may have cancer.

Change Healthcare expects full operations to resume next year, according to its chief financial officer. Two months after a ...

A hematology and oncology practice in Texas entered into an unlawful kickback arrangement with a diagnostic reference laboratory.

Glecirasib, a KRAS G12C inhibitor, has demonstrated activity in a phase 2 trial of patients with KRAS G12C-mutated, advanced non-small cell lung cancer (NSCLC).

A lack of information on drug shortages can make it difficult to identify and respond to shortages appropriately, but improving supply chain transparency and federal oversight could reduce or prevent ...

Cancer drugs approved under the FDA's Real-Time Oncology Review program may not be supported by adequate trial data, researchers suggested.

Study results support the omission of ALND in patients with breast cancer who have node-negative disease after SLNB or TAD, according to researchers.